| Akebia Therapeutics is a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease. Co.'s portfolio includes: Vadadustat, which is an investigational, oral hypoxia-inducible factor prolyl hydroxylase inhibitor for two indications, anemia due to chronic kidney disease (CKD), in adult patients on dialysis, and anemia due to CKD in adult patients not on dialysis; and Auryxia® (ferric citrate), for the control of serum phosphorus levels in adult patients on dialysis, or the Hyperphosphatemia Indication, and the treatment of iron deficiency anemia (IDA) in adult patients not on dialysis, or the IDA Indication; We show 30 historical shares outstanding datapoints in our coverage of AKBA's shares outstanding history.|
Understanding the changing numbers of AKBA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AKBA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AKBA by allowing them to research AKBA shares outstanding history
as well as any other stock in our coverage universe.